

PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 76722

Title: Albumin administration in patients with cirrhosis – current role and novel perspectives

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 00504581

Position: Editorial Board

Academic degree: MD, PhD

Professional title: Associate Chief Physician, Associate Specialist, Attending Doctor,

Doctor, Medical Assistant, Staff Physician

Reviewer's Country/Territory: Spain

Author's Country/Territory: Brazil

Manuscript submission date: 2022-03-27

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-03-28 07:45

Reviewer performed review: 2022-04-05 17:29

Review time: 8 Days and 9 Hours

Scientific quality	[] Grade A: Excellent [Y] Grade B: Very good [] Grade C: Good [] Grade D: Fair [] Grade E: Do not publish
Language quality	 [] Grade A: Priority publishing [Y] Grade B: Minor language polishing [] Grade C: A great deal of language polishing [] Grade D: Rejection
Conclusion	 [] Accept (High priority) [Y] Accept (General priority) [] Minor revision [] Major revision [] Rejection





Re-review	[Y]Yes []No
Peer-reviewer	Peer-Review: [Y] Anonymous [] Onymous
statements	Conflicts-of-Interest: [] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

The authors make an interesting review and sum up a topic very well known, with internationally established, accepted, and approved guidelines about the use of albumin in specific different settings. Besides, they also discussed other scenarios with a more debatable indication and results, such as Extraperitoneal infections, Long-term albumin administration, and other indications. However, until now there is not reaching a unanimous consensus. It results in an interesting discussion showing the importance of the albumin as a multifunctional protein, which also has important non-oncotic properties The only thing I missed in this report was to evaluate and discuss the economic cost of these approaches



PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 76722

Title: Albumin administration in patients with cirrhosis – current role and novel perspectives

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 06151472

Position: Peer Reviewer

Academic degree: MD

Professional title: Doctor

Reviewer's Country/Territory: Italy

Author's Country/Territory: Brazil

Manuscript submission date: 2022-03-27

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-04-19 06:13

Reviewer performed review: 2022-04-19 16:07

Review time: 9 Hours

Scientific quality	[] Grade A: Excellent [] Grade B: Very good [Y] Grade C: Good [] Grade D: Fair [] Grade E: Do not publish
Language quality	 [] Grade A: Priority publishing [Y] Grade B: Minor language polishing [] Grade C: A great deal of language polishing [] Grade D: Rejection
Conclusion	 [] Accept (High priority) [] Accept (General priority) [] Minor revision [Y] Major revision [] Rejection
Re-review	[Y]Yes []No



Baishideng

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA Telephone: +1-925-399-1568 E-mail: bpgoffice@wjgnet.com https://www.wjgnet.com

Peer-reviewer	Peer-Review: [Y] Anonymous [] Onymous
statements	Conflicts-of-Interest: [] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

This was a well-written review on the current indications to albumin use in patients with cirrhosis, especially those with decompensated cirrhosis. The Authors remarked the most common indications, as large volume paracentesis, AKI, AKI-HRS, spontaneous bacterial peritonitis. Further, they mentioned potentially innovative indications, as long-term administration for outpatients with ascites, that will probably be recommended in the next future. The paper is of interest, and well-updated, since it discusses many recently published papers. My comments: - I do not see any information about cost-effectiveness of albumin. - I do not see any information about potential side effects of albumin (other than volume overload), for instance, infusion-related side effects. - The Authors said that albumin has anti-inflammatory properties. What about its role in patients with ACLF who do not fulfill criteria of HRS, SBP? Are there studies that demonstrate the reduction of proinflammatory biomarkers after albumin infusion? - Has albumin role been investigated in patients with cardiac derangements related to cirrhosis? - I think that a brief comment on the importance of a functionally active albumin would be of help - In clinical practice, albumin is useful for many patients, but it is not a magic medication for all. For instance, many patients with SBP who are treated with albumin and antibiotics develop HRS-AKI. Biomarkers that predict the response to albumin and that could stratify its use are currently lacking. A comment would be valuable.



RE-REVIEW REPORT OF REVISED MANUSCRIPT

Name of journal: *World Journal of Gastroenterology*

Manuscript NO: 76722

Title: Albumin administration in patients with cirrhosis – current role and novel perspectives

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 06151472

Position: Peer Reviewer

Academic degree: MD

Professional title: Doctor

Reviewer's Country/Territory: Italy

Author's Country/Territory: Brazil

Manuscript submission date: 2022-03-27

Reviewer chosen by: Ya-Juan Ma

Reviewer accepted review: 2022-06-15 15:03

Reviewer performed review: 2022-06-15 15:07

Review time: 1 Hour

Scientific quality	[] Grade A: Excellent [Y] Grade B: Very good [] Grade C: Good [] Grade D: Fair [] Grade E: Do not publish
Language quality	 [] Grade A: Priority publishing [Y] Grade B: Minor language polishing [] Grade C: A great deal of language polishing [] Grade D: Rejection
Conclusion	 [] Accept (High priority) [Y] Accept (General priority) [] Minor revision [] Major revision [] Rejection
Peer-reviewer	Peer-Review: [Y] Anonymous [] Onymous





statements

Conflicts-of-Interest: [] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

The authors fairly answered my previous comments. No further action.